Avinash Ramu

Avinash Ramu

Auto-generated profile, based on publicly available information

Avinash Ramu

The Edison Family Center for Genome Sciences and Systems Biology, School of Medicine, Washington University in St. Louis

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 January 2017 in Nature Genetics
Verified
Journal Article
Open access
PDF file
MGMalachi Griffith
Malachi Griffith
NSNicholas C Spies
Nicholas C Spies
KKKilannin Krysiak
Kilannin Krysiak
JMJoshua F McMichael
Joshua F McMichael
ACAdam C Coffman
Adam C Coffman
OGObi L Griffith
Obi L Griffith
CIViC is an expert-crowdsourced knowledgebase for Clinical Interpretation of Variants in Cancer describing the therapeutic, prognostic, diagnostic and predisposing relevance of inherited and somatic variants of all types. CIViC is committed to open-source code, open-access content, public application programming interfaces (APIs) and provenance of supporting evidence to allow for the transparent creation of current and accurate variant interpretations for use in cancer precision medicine.

12 October 2017 in Nature
Verified
Journal Article
Closed access
PDF file
GCGTEx Consortium
GTEx Consortium
MTMeng How Tan
Meng How Tan
QLQin Li
Qin Li
RSRaghuvaran Shanmugam
Raghuvaran Shanmugam
RPRobert Piskol
Robert Piskol
JLJin Billy Li
Jin Billy Li

17 November 2014 in Nature
Verified
Journal Article
Open access
PDF file
DJDejan Juric
Dejan Juric
PCPau Castel
Pau Castel
MGMalachi Griffith
Malachi Griffith
OGObi L. Griffith
Obi L. Griffith
HWHelen H. Won
Helen H. Won
MSMaurizio Scaltriti
Maurizio Scaltriti
A study of genome evolution in a metastatic breast cancer bearing an activating PIK3CA mutation, following treatment with the PI(3)Kα inhibitor BYL719, shows that all metastatic lesions, when compared to the pre-treatment tumour, had lost a copy of PTEN; parallel genetic evolution of separate sites with different PTEN genomic alterations had led to a convergent PTEN-null phenotype resistant to PI(3)Kα inhibition. The emergence and expansion of resistant clonal subpopulations is a major challenge facing the field of targeted therapeutics. Here, the authors study genome evolution in a metastatic breast cancer bearing an activating PIK3CA mutation, following treatment with the phosphatidylinositol-4,5-bisphosphate 3-kinase alpha subunit (PI(3)Kα) selective-inhibitor BYL719. Fourteen metastatic sites were sequenced to reveal that all metastatic lesions, when compared to the pre-treatment tumour, had lost a copy of the gene for the tumour suppressor phosphatase PTEN. Resistance to BYL719 was associated with additional and different PTEN genetic alterations, resulting in loss of PTEN expression. Based on these observations and additional functional characterization, the authors conclude that parallel genetic evolution of separate sites with different PTEN genomic alterations leads to a convergent PTEN-null phenotype resistant to PI(3)Kα inhibition. Broad and deep tumour genome sequencing has shed new light on tumour heterogeneity and provided important insights into the evolution of metastases arising from different clones1,2. There is an additional layer of complexity, in that tumour evolution may be influenced by selective pressure provided by therapy, in a similar fashion to that occurring in infectious diseases. Here we studied tumour genomic evolution in a patient (index patient) with metastatic breast cancer bearing an activating PIK3CA (phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha, PI(3)Kα) mutation. The patient was treated with the PI(3)Kα inhibitor BYL719, which achieved a lasting clinical response, but the patient eventually became resistant to this drug (emergence of lung metastases) and died shortly thereafter. A rapid autopsy was performed and material from a total of 14 metastatic sites was collected and sequenced. All metastatic lesions, when compared to the pre-treatment tumour, had a copy loss of PTEN (phosphatase and tensin homolog) and those lesions that became refractory to BYL719 had additional and different PTEN genetic alterations, resulting in the loss of PTEN expression. To put these results in context, we examined six other patients also treated with BYL719. Acquired bi-allelic loss of PTEN was found in one of these patients, whereas in two others PIK3CA mutations present in the primary tumour were no longer detected at the time of progression. To characterize our findings functionally, we examined the effects of PTEN knockdown in several preclinical models (both in cell lines intrinsically sensitive to BYL719 and in PTEN-null xenografts derived from our index patient), which we found resulted in resistance to BYL719, whereas simultaneous PI(3)K p110β blockade reverted this resistance phenotype. We conclude that parallel genetic evolution of separate metastatic sites with different PTEN genomic alterations leads to a convergent PTEN-null phenotype resistant to PI(3)Kα inhibition.

1 September 2015 in Cell Systems
Verified
Journal Article
Closed access
MGMalachi Griffith
Malachi Griffith
CMChristopher A. Miller
Christopher A. Miller
OGObi L. Griffith
Obi L. Griffith
KKKilannin Krysiak
Kilannin Krysiak
ZSZachary L. Skidmore
Zachary L. Skidmore
RWRichard K. Wilson
Richard K. Wilson

25 August 2013 in Nature Methods
Verified
Journal Article
Closed access
PDF file
ARAvinash Ramu
Avinash Ramu
MNMichiel J Noordam
Michiel J Noordam
RSRachel S Schwartz
Rachel S Schwartz
AWArthur Wuster
Arthur Wuster
MHMatthew E Hurles
Matthew E Hurles
DCDonald F Conrad
Donald F Conrad

17 September 2018 in Nature Communications
Verified
Journal Article
Open access
PDF file
AWAlex H. Wagner
Alex H. Wagner
SDSiddhartha Devarakonda
Siddhartha Devarakonda
ZSZachary L. Skidmore
Zachary L. Skidmore
KKKilannin Krysiak
Kilannin Krysiak
ARAvinash Ramu
Avinash Ramu
RGRamaswamy Govindan
Ramaswamy Govindan
Nearly all patients with small cell lung cancer (SCLC) eventually relapse with chemoresistant disease. The molecular mechanisms driving chemoresistance in SCLC remain un-characterized. Here, we describe whole-exome sequencing of paired SCLC tumor samples procured at diagnosis and relapse from 12 patients, and unpaired relapse samples from 18 additional patients. Multiple somatic copy number alterations, including gains in ABCC1 and deletions in MYCL, MSH2, and MSH6, are identifiable in relapsed samples. Relapse samples also exhibit recurrent mutations and loss of heterozygosity in regulators of WNT signaling, including CHD8 and APC. Analysis of RNA-sequencing data shows enrichment for an ASCL1-low expression subtype and WNT activation in relapse samples. Activation of WNT signaling in chemosensitive human SCLC cell lines through APC knockdown induces chemoresistance. Additionally, in vitro-derived chemoresistant cell lines demonstrate increased WNT activity. Overall, our results suggest WNT signaling activation as a mechanism of chemoresistance in relapsed SCLC.